ARFGEF2
protein-codingADP ribosylation factor guanine nucleotide exchange factor 2, the group of Armadillo like helical domain containing|ARFGEF family|A-kinase anchoring proteins
Gene summary
ADP-ribosylation factors (ARFs) play an important role in intracellular vesicular trafficking. The protein encoded by this gene is involved in the activation of ARFs by accelerating replacement of bound GDP with GTP and is involved in Golgi transport. It contains a Sec7 domain, which may be responsible for its guanine-nucleotide exchange activity and also brefeldin A inhibition. [provided by RefSeq, Jul 2008]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~115.0 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0011966
Submitter: ClinGen
ARFGEF2 was first reported in connection to autosomal recessive periventricular heterotopia with microcephaly in 2004 (Sheen et al., 2004 PMID:14647276). Common phenotypes for individuals with ARFGEF2 - periventricular heterotopia with microcephaly include progressive microcephaly, severe GDD/ID, hypotonia, spasticity, hyperkinetic movement disorder, epilepsy, failure to thrive, cardiomyopathy, corpus callosum thinning, and putamen T2 hyperintensity/atrophy. Nine unique variants of different types (3 frameshift, 2 missense, 2 nonsense, 1 canonical splice site) reported in seven probands have been included in this curation (PMID:14647276, 19384555, 23755938, 23812912, 25160555, 26126837). The presumed mechanism is loss of function. The maximum score for genetic evidence (12 pts.) has been reached. This gene-disease relationship is further supported by functional alteration, protein interaction, and expression data (PMID:16320251, 14647276). In summary, there is definitive evidence to support the relationship between ARFGEF2 and autosomal recessive periventricular heterotopia with microcephaly. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Brain Malformations expert panel on 09/12/2023 (SOP Version 9).
Inheritance Pattern: AD
Disease ID:MONDO:0020341
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0011966
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0011966
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0011966
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
Comments: In addition to neurologic manifestations, cardiomyoptathy and frequent infections have been described, but this finding may be coincidental; Recurrent infections have been described in several individuals, but it is unclear if this is a primary manifestation or secondary to neurodegenerative sequelae
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to ARFGEF2 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_006420.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 14 | 156 | 4 | 174 | ||
| missense | 350 | 16 | 1 | 367 | ||
| nonsense | 7 | 6 | 2 | 15 | ||
| start loss | 0 | |||||
| frameshift | 6 | 5 | 2 | 13 | ||
| splice donor/acceptor (+/-2bp) | 2 | 3 | 11 | 16 | ||
| Total | 15 | 14 | 379 | 172 | 5 | 585 |
Highest pathogenic variant AF is 0.000006572461
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_006411.2 | 39 | MANE Select | |
| Ensembl | ENSP00000360985.4 | 39 | MANE Select | |
| RefSeq | NP_001397775.1 | 39 | Standard | |
| Ensembl | ENSP00000504888.1 | 39 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Endocytosis - Homo sapiens (human)
- thrombin signaling and protease-activated receptors
- Metabolism of proteins
- Chaperonin-mediated protein folding
- Association of TriC/CCT with target proteins during biosynthesis
Biological Process
- receptor recycling
- exocytosis
- Golgi to plasma membrane transport
- endosome organization
- endomembrane system organization
Molecular Function
- guanyl-nucleotide exchange factor activity
- ARF guanyl-nucleotide exchange factor activity
- protein binding
- myosin binding
- protein kinase A regulatory subunit binding
Cellular Component
- Golgi membrane
- trans-Golgi network
- microtubule organizing center
- cytosol
- axonemal microtubule
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000371917
- Coding exons
- 39
- Length
- 114804
- Individuals with no LoFs
- 125722
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 26
- Defined
- 125748
- p
- 0.000103
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 2.60 | 731 | 957 | 0.764 | 0.0000560 | 11827 |
| Missense (PolyPhen) | 92 | 207.44 | 0.44351 | 2537 | ||
| Synonymous | 0.822 | 340 | 360 | 0.945 | 0.0000222 | 3335 |
| Loss of Function | 7.65 | 16 | 97.5 | 0.164 | 0.00000557 | 1127 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00038 | 0.00037 | rare |
| Latino/Admixed American | 0.000058 | 0.000058 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00011 | 0.00011 | rare |
| Finnish | 0.000092 | 0.000092 | rare |
| European (Non-Finnish) | 0.000088 | 0.000079 | rare |
| South Asian | 0.00016 | 0.00016 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Promotes guanine-nucleotide exchange on ARF1 and ARF3 and to a lower extent on ARF5 and ARF6. Promotes the activation of ARF1/ARF5/ARF6 through replacement of GDP with GTP. Involved in the regulation of Golgi vesicular transport. Required for the integrity of the endosomal compartment. Involved in trafficking from the trans-Golgi network (TGN) to endosomes and is required for membrane association of the AP-1 complex and GGA1. Seems to be involved in recycling of the transferrin receptor from recycling endosomes to the plasma membrane. Probably is involved in the exit of GABA(A) receptors from the endoplasmic reticulum. Involved in constitutive release of tumor necrosis factor receptor 1 via exosome-like vesicles; the function seems to involve PKA and specifically PRKAR2B. Proposed to act as A kinase-anchoring protein (AKAP) and may mediate crosstalk between Arf and PKA pathways. {ECO:0000269|PubMed:12051703, ECO:0000269|PubMed:12571360, ECO:0000269|PubMed:15385626, ECO:0000269|PubMed:16477018, ECO:0000269|PubMed:17276987, ECO:0000269|PubMed:18625701, ECO:0000269|PubMed:20360857}.;
- Disease
- DISEASE: Periventricular nodular heterotopia 2 (PVNH2) [MIM:608097]: A developmental disorder characterized by the presence of periventricular nodules of cerebral gray matter, resulting from a failure of neurons to migrate normally from the lateral ventricular proliferative zone, where they are formed, to the cerebral cortex. PVNH2 is an autosomal recessive form characterized by microcephaly (small brain), severe developmental delay and recurrent infections. No anomalies extrinsic to the central nervous system, such as dysmorphic features or grossly abnormal endocrine or other conditions, are associated with PVNH2. {ECO:0000269|PubMed:14647276, ECO:0000269|PubMed:23812912, ECO:0000269|PubMed:25160555}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.150
Intolerance Scores
- LoFtool
- 0.395
- RVIS EVS
- -2.39
- RVIS percentile EVS
- 1.1
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.951
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |